Keyword: AC Immune

The setback wipes out near-term hopes of getting the AC Immune-partnered anti-Abeta antibody crenezumab to market.

The deal gives Lilly ownership of a small molecule that has inhibited tau aggregation in preclinical models.

In our EuroBiotech roundup this week, Genmab, Ipsen and Nucana post clinical cancer data, Advicenne phase 3 hits endpoint and TiGenix makes U.S. hires.

In our EuroBiotech roundup this week, Ablynx puts partnering plan on ice, Merck KGaA backs I-O startup and Destiny files for IPO.

Roche is doubling down on its anti-amyloid beta antibody crenezumab with a second phase 3 Alzheimer's trial.

AC Immune is offloading 6 million IPO shares, 32% more than originally planned, at the bottom end of its targeted $11 to $13 price range.

Biotech reverse mergers are becoming more acceptable and are more commonplace this year. But startups are already ramping up for IPOs during the first half of 2017.

Alzheimer’s specialist AC Immune, which lists Biogen, Genentech and Johnson & Johnson among its partners, has set the terms for its long-mooted Nasdaq IPO.

Three weeks after putting the finishing touches to a $43.5 million E round, AC Immune has jumped into the IPO queue.

Genentech-partnered AC Immune has added $43.5 million in venture cash to its reserves.